Thomas Gad Sells 4,000 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Share on StockTwits

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $21.77, for a total value of $87,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Thomas Gad also recently made the following trade(s):

  • On Monday, June 10th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.79, for a total value of $91,160.00.
  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.21, for a total value of $121,260.00.
  • On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.61, for a total value of $123,660.00.
  • On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $25.89, for a total value of $6,472,500.00.

Shares of NASDAQ:YMAB opened at $22.53 on Thursday. Y-mAbs Therapeutics, Inc has a 52-week low of $15.17 and a 52-week high of $31.00. The company has a market capitalization of $740.29 million and a PE ratio of -15.02. The business has a 50 day moving average price of $21.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.07). As a group, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc will post -1.95 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Citigroup Inc. bought a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $37,000. BNP Paribas Arbitrage SA bought a new position in Y-mAbs Therapeutics in the first quarter worth approximately $38,000. American International Group Inc. bought a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $93,000. Bank of America Corp DE grew its stake in Y-mAbs Therapeutics by 3,056.5% in the fourth quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after purchasing an additional 5,838 shares in the last quarter. Finally, Deutsche Bank AG bought a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $191,000. 24.80% of the stock is currently owned by institutional investors.

YMAB has been the topic of several recent analyst reports. Zacks Investment Research downgraded Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 20th. HC Wainwright set a $36.00 price target on Y-mAbs Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 28th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $30.80.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Read More: What is the price-sales ratio?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.